Non-GLP-1 Weight Loss Medications: Evidence-Based Alternatives

Last reviewed: May 19, 2026

Last updated: May 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Non-GLP-1 weight loss medications provide evidence-based alternatives for patients exploring options beyond incretin mimetics. These include phentermine, orlistat, naltrexone-bupropion, and other agents with distinct mechanisms targeting appetite, absorption, or neurochemical pathways. Each carries different efficacy profiles, side effect tolerability, and clinical suitability depending on individual health status and treatment history.

Understanding why a patient may respond differently to non-GLP-1 agents requires evaluating both clinical factors and underlying metabolic markers. PlexusDx precision-wellness approach examines genetic predispositions in weight-regulation pathways to help providers and patients contextualize treatment choices within a more personalized framework, rather than defaulting to trial-and-error medication selection.

How Non-GLP-1 Medications Work: Distinct Metabolic Pathways

Non-GLP-1 weight loss agents operate through mechanistically different pathways than incretin-based therapies. Phentermine stimulates central nervous system catecholamine release to reduce appetite. Orlistat inhibits pancreatic lipase, reducing dietary fat absorption by approximately 30 percent. Naltrexone-bupropion combines opioid antagonism with dopamine and norepinephrine reuptake inhibition to modulate hunger and reward centers.

Understanding these distinct mechanisms matters because patient response varies significantly based on which pathway is most relevant to their metabolic phenotype. Genetic variations in dopamine receptors, appetite-regulatory peptide systems, and lipid metabolism influence how well each medication may work for an individual. Provider assessment should consider both mechanism fit and individual metabolic markers.

Clinical Evidence and Efficacy Comparison of Common Non-GLP-1 Agents

Clinical trial data shows varying weight loss outcomes across non-GLP-1 options. Phentermine typically produces 3 to 7 percent body weight reduction over 12 weeks. Orlistat achieves approximately 2.5 to 3.5 percent weight loss. Naltrexone-bupropion (Contrave) demonstrates 5 to 9 percent reduction in pivotal trials. These differences reflect mechanistic variations and individual patient factors influencing medication response.

Medication	Primary Mechanism	Typical Weight Loss Range	Common Limiting Factors
Phentermine	CNS stimulant (catecholamine)	3–7% over 12 weeks	Tachycardia, insomnia, tolerance
Orlistat	Lipase inhibitor (absorption)	2.5–3.5% over 24 weeks	GI side effects, fat-soluble vitamin absorption
Naltrexone-Bupropion	Opioid antagonist + dopamine/NE reuptake	5–9% over 56 weeks	Nausea, seizure risk with bupropion
Metformin (off-label)	Insulin sensitivity, GI glucose absorption	2–3% in insulin-resistant populations	GI intolerance, B12 depletion with long-term use

Genetic Predispositions and Metabolic Markers Influencing Non-GLP-1 Response

Genetic variations in appetite-regulatory genes, dopamine signaling, and lipid metabolism pathways influence how individuals respond to non-GLP-1 agents. Variants in FTO, MC4R, and GIPR genes correlate with baseline weight-gain susceptibility and may inform which mechanism of action best addresses an individual's metabolic phenotype. Biomarker assessment can support more targeted medication selection.

For example, patients with genetic predispositions toward reduced dopamine sensitivity may benefit more from naltrexone-bupropion's dopamine-enhancing mechanism than from appetite suppressants alone. Conversely, individuals with high fat absorption capacity might see greater benefit from orlistat's lipase-inhibition pathway. Provider consultation with genetic and biomarker context enables more informed medication matching.

Safety Considerations, Contraindications, and Who This Treatment Applies To

Non-GLP-1 medications carry distinct safety profiles and contraindications requiring careful provider evaluation. Phentermine is contraindicated in uncontrolled hypertension, cardiac disease, and hyperthyroidism due to sympathomimetic effects. Orlistat requires monitoring for fat-soluble vitamin absorption and is not suitable for chronic malabsorption disorders. Naltrexone-bupropion carries black-box warnings regarding neuropsychiatric effects and seizure risk, particularly in patients with prior seizures or psychiatric conditions.

Non-GLP-1 agents are most appropriate for patients unable to tolerate GLP-1 medications, those with GLP-1 contraindications (such as personal or family history of medullary thyroid carcinoma), or individuals requiring different metabolic pathways. Comprehensive medical evaluation, including cardiovascular assessment, baseline labs, and psychiatric screening where indicated, should precede initiation. Ongoing monitoring ensures safety and efficacy alignment with individual health status.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test may help provide context regarding genetic predispositions in weight-regulation pathways, including FTO rs9939609, MC4R rs17782313, GLP1R rs6923761, and GIPR rs1800437 variants. These variants relate to baseline weight-gain susceptibility and metabolic flexibility, informing which non-GLP-1 mechanisms may align with an individual's biological profile. Results should always be interpreted with a qualified healthcare provider in the context of clinical assessment.

The genetic test reveals predispositions in peptide and metabolic pathways relevant to weight loss medication response, but does not predict exact medication outcomes or guarantee efficacy. Genetic information complements—rather than replaces—clinical evaluation, medical history, biomarker labs (glucose, lipid profile, liver and kidney function), and provider judgment. Understanding genetic context may reduce trial-and-error medication cycling by highlighting mechanisms most aligned with metabolic phenotype.

Discussing genetic predisposition results with your provider supports a more personalized conversation about which non-GLP-1 agent may warrant consideration first. For example, results showing predisposition toward reduced dopamine sensitivity might prompt discussion of naltrexone-bupropion efficacy. PlexusDx genetic insights, combined with comprehensive metabolic assessment, empower more informed shared decision-making around medication selection and realistic outcome expectations.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.